Risk of osteoporotic fractures after discontinuation of menopausal hormone therapy: Results from the E3N Cohort

American Journal of Epidemiology

Volumn 174, Issue 1, 2011, Pages 12-21

  Engel, Pierre ^a   Fabre, Alban ^a   Fournier, Agns ^a   Mesrine, Sylvie ^a   Boutron Ruault, Marie Christine ^a   Clavel Chapelon, Franoise ^a  

^a INSERM   (France)

Author keywords

cohort studies; estrogen replacement therapy; osteoporosis; osteoporotic fractures; postmenopause

Indexed keywords

ESTROGEN;

COHORT ANALYSIS; EPIDEMIOLOGY; ESTROGENIC COMPOUND; HEALTH RISK; HORMONE; MULTIVARIATE ANALYSIS; OSTEOLOGY; WOMENS HEALTH;

ADULT; ARTICLE; COHORT ANALYSIS; DRUG USE; FEMALE; FRAGILITY FRACTURE; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL HORMONE THERAPY; POSTMENOPAUSE; TREATMENT WITHDRAWAL;

ADULT; AGED; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FRACTURES, SPONTANEOUS; FRANCE; HIP FRACTURES; HUMANS; LIFE STYLE; MENOPAUSE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; OSTEOPOROTIC FRACTURES; POSTMENOPAUSE; PROGESTINS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK ASSESSMENT; RISK FACTORS; SPINAL FRACTURES; TIME FACTORS; WITHHOLDING TREATMENT; WRIST INJURIES;

FRANCE;

EID: 79959657630     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwr044     Document Type: Article

References (41)

1. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17(12):1726-1733. (Pubitemid 44607392)
2. Management of osteoporosis in postmenopausal women: 2010 position statement of the North American Menopause Society. Menopause. 2010;17(1):25-54.
3. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785-795.
4. Geusens P, Milisen K, Dejaeger E, et al. Falls and fractures in postmenopausal women: a review. J Br Menopause Soc. 2003;9(3):101-106. (Pubitemid 37203503)
5. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials. BMC Musculoskelet Disord. 2001;2:7. (doi: 10.1186/1471-2474-2-7).
6. Cauley JA, Robbins J, Chen Z, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA. 2003; 290(13):1729-1738. (Pubitemid 37430623)
7. Torgerson DJ, Bell-Syer SE. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA. 2001;285(22):2891-2897. (Pubitemid 32537354)
8. Jackson RD, Wactawski-Wende J, LaCroix AZ, et al. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the Women's Health Initiative randomized trial. J Bone Miner Res. 2006;21(6):817-828. (Pubitemid 43787988)
9. Wells G, Tugwell P, Shea B, et al. Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr Rev. 2002;23(4):529-539. (Pubitemid 34925647)
10. Banks E, Beral V, Reeves G, et al. Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA. 2004;291(18):2212-2220. (Pubitemid 38608170)
11. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA. 2002; 288(7):872-881.
12. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333. (Pubitemid 34761611)
13. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Million Women Study Collaborators. Lancet. 2003;362(9382):419-427. (Pubitemid 36999703)
14. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA. 2003;289(24):3243-3253. (Pubitemid 37430077)
15. Verkooijen HM, Bouchardy C, Vinh-Hung V, et al. The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. Maturitas. 2009;64(2):80-85.
16. Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA. 2008;299(9): 1036-1045. (Pubitemid 351347060)
17. Michaëlsson K, Baron JA, Johnell O, et al. Variation in the efficacy of hormone replacement therapy in the prevention of hip fracture. Swedish Hip Fracture Study Group. Osteoporos Int. 1998;8(6):540-546. (Pubitemid 28566968)
18. Vestergaard P, Rejnmark L, Mosekilde L. Fracture reducing potential of hormone replacement therapy on a population level. Maturitas. 2006;54(3):285-293. (Pubitemid 44250807)
19. Van Liere MJ, Lucas F, Clavel F, et al. Relative validity and reproducibility of a French dietary history questionnaire. Int J Epidemiol. 1997;26(suppl 1):S128-S136. (Pubitemid 27129697)
20. Center JR, Bliuc D, Nguyen TV, et al. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA. 2007;297(4):387-394. (Pubitemid 46155800)
21. Clavel-Chapelon F, Dormoy-Mortier N. A validation study on status and age of natural menopause reported in the E3N cohort. Maturitas. 1998;29(2):99-103. (Pubitemid 28267268)
22. Dargent-Molina P, Sabia S, Touvier M, et al. Proteins, dietary acid load, and calcium and risk of postmenopausal fractures in the E3N French women prospective study. J Bone Miner Res. 2008;23(12):1915-1922.
23. Samelson EJ, Zhang Y, Kiel DP, et al. Effect of birth cohort on risk of hip fracture: age-specific incidence rates in the Framingham Study. Am J Public Health. 2002;92(5): 858-862. (Pubitemid 34441644)
24. Manolagas SC, Kousteni S, Jilka RL. Sex steroids and bone. Recent Prog Horm Res. 2002;57(1):385-409.
25. Barengolts EI, Gajardo HF, Rosol TJ, et al. Effects of progesterone on postovariectomy bone loss in aged rats. J Bone Miner Res. 1990;5(11):1143-1147. (Pubitemid 20373522)
26. Tremollieres FA, Strong DD, Baylink DJ, et al. Progesterone and promegestone stimulate human bone cell proliferation and insulin-like growth factor-2 production. Acta Endocrinol (Copenh). 1992;126(4):329-337.
27. Bland R. Steroid hormone receptor expression and action in bone. Clin Sci (Lond). 2000;98(2):217-240. (Pubitemid 30105532)
28. Barrett-Connor E, Wehren LE, Siris ES, et al. Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study. Menopause. 2003;10(5): 412-419.
29. Bagger YZ, Tankó LB, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone. 2004;34(4): 728-735. (Pubitemid 38393810)
30. Keegan TH, Gopalakrishnan G, Sidney S, et al. Hormone replacement therapy and risk for foot, distal forearm, proximal humerus, and pelvis fractures. Osteoporos Int. 2003;14(6): 469-475. (Pubitemid 36919206)
31. Corrao G, Zambon A, Nicotra F, et al. Issues concerning the use of hormone replacement therapy and risk of fracture: a population-based, nested case-control study. Br J Clin Pharmacol. 2008;65(1):123-129. (Pubitemid 350265159)
32. Greendale GA, Espeland M, Slone S, et al. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. Arch Intern Med. 2002;162(6):665-672. (Pubitemid 34226393)
33. Christiansen C, Christensen MS, Transbol I. Bone mass after withdrawal of oestrogen replacement. Lancet. 1981;1(8228): 1053-1054. (Pubitemid 11096640)
34. Cauley JA, Seeley DG, Ensrud K, et al. Estrogen replacement therapy and fractures in older women. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 1995;122(1):9-16.
35. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359(7):697-708.
36. Banks E, Beral V, Cameron R, et al. Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. J Epidemiol Biostat. 2001;6(4):357-363. (Pubitemid 33138827)
37. Ivers RQ, Cumming RG, Mitchell P, et al. The accuracy of self-reported fractures in older people. J Clin Epidemiol. 2002;55(5):452-457. (Pubitemid 34462240)
38. Nevitt MC, Cummings SR, Browner WS, et al. The accuracy of self-report of fractures in elderly women: evidence from a prospective study. Am J Epidemiol. 1992;135(5):490-499.
39. Chen Z, Kooperberg C, Pettinger MB, et al. Validity of self-report for fractures among a multiethnic cohort of postmenopausal women: results from the Women's Health Initiative observational study and clinical trials. Menopause. 2004;11(3):264-274. (Pubitemid 40362180)
40. O'Neill TW, Felsenberg D, Varlow J, et al. The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res. 1996;11(7):1010-1018. (Pubitemid 26200053)
41. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone. 2004; 35(2):375-382. (Pubitemid 38953182)